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Abstract
This study of 135 serotype 1 pneumococcal isolates (88 invasive
and 47 non-invasive), collected between 1987 and 2007, gave eight
sequence types (217, 227, 228, 304, 305, 306, 3860 and 3861) that
group, using eBurst, into three different lineages and one single-
ton. The annual incidence of serotype 1 invasive episodes per
million inhabitants increased from 1.8 in 1987–1993 to 4.0 in
1994–2000, and to 25.6 in 2001–2007. ST228 was the predomi-
nant clone until 1998. ST306 ﬁrst appeared in 1998 and became
the most prevalent sequence type (>80%) after the introduction,
in June 2001, of the heptavalent pneumococcal conjugate vaccine.
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Streptococcus pneumoniae serotype 1 is considered a primary
pathogen, since it is more frequently isolated from sterile
locations than from non-sterile samples or carriers [1].
Indeed, serotype 1 has been associated with outbreaks
of invasive disease [2]. At the beginning of the 21st century,
the 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced for children. Vaccination has changed the distri-
bution of serotypes causing invasive pneumococcal disease in
children, substantially decreasing the incidence of vaccine
serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and
increasing some of the serotypes not included in this vaccine
[3–5]. The objective of this study was to determine the clo-
nal structure and evolution of serotype 1 isolates causing
invasive and non-invasive disease in a region of northern
Spain in the last 21 years.
This study was performed in the region of Gipuzkoa,
Basque Country, northern Spain, a province bordered by the
Bay of Biscay and France. This region includes the areas of
San Sebastia´n, Tolosa and most of the villages belonging to
the Urola Coastal area. Population data were based on the
ofﬁcial censuses for 1991, 1996, 2001 and 2006 (Eustat,
http://www.eustat.es). The PCV7 was introduced in Spain in
June 2001 and approximately 50% of children aged <2 years
have been vaccinated in the study region [6].
Overall, 135 non-duplicated serotype 1 isolates were studied.
Between 1987 and 2007, 88 (7.28%) out of 1209 pneumococ-
cal isolates causing invasive disease in the population-based
area of the study were serotype 1. The remaining isolates
were: 24 from the ear ﬂuid of children with otitis and 23 from
the sputum of adults with respiratory infection (Table 1). The
identiﬁcation, serotyping and genotyping by pulsed ﬁeld gel
electrophoresis (PFGE) were performed according to previ-
ously described standard protocols [7]. Antimicrobial suscepti-
bility [8] and multilocus sequence typing (MLST) [9] were
performed as described previously.
MLST was performed on all isolates and yielded eight dif-
ferent sequence types (STs) (http://spneumoniae.mlst.net/
eburst/). The 135 isolates were grouped by eBURSTv3 into
three lineages, arbitrarily named I to III, and, if only serotype I
isolates included in the MLST database were considered, one
singleton, ST3860 (Table 2). According to eBURST, the STs
in each lineage were evolutionarily related. MLST-lineage-I
included most of the serotype 1 isolates (123/135, 91.1%).
The singleton is a newly described ST3860 (single locus vari-
ant of ST1340), probably resulting from genetic switching of a
capsular type 19F isolate, since ST3860 was the only compo-
nent of this lineage that was not serotype 19F.
The eight different MLST-types coincided with the PFGE
patterns when the latter were deﬁned by a similarity of
‡85% (Table 2). When a PFGE similarity of between 85%
and <95% was considered in the clustering analysis of type A
isolates, these could be further divided into six subtypes
(arbitrarily named A1–A6) (Table 2).
All 135 serotype 1 isolates were penicillin-susceptible
(MIC <0.12 mg/L), rifampicin-susceptible (MIC <2 mg/L)
and erythromycin-susceptible (MIC <0.50 mg/L); one was
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trimethoprim-sulfamethoxazole-resistant (MIC >4/76), three
were ciproﬂoxacin-resistant (MIC ‡4 mg/L), and two tetracy-
cline-resistant (MIC ‡4 mg/L).
The absolute number and incidence of invasive serotype 1
isolates increased throughout the period of study (Table 1).
This increase was non-signiﬁcant between 1987–1993 and
1994–2000, but signiﬁcant between each of the subsequent
periods and 2001–2007 (p <0.0001). The difference remained
signiﬁcant when comparing each age group separately, except
for the under-ﬁve age group. In this age group, perhaps
due to the low number of cases, signiﬁcance was evident
only when comparing the ﬁrst and last periods (chi-square
with Yates correction v2 Yates = 5.53, p 0.019). Because the
PCV7 vaccine was introduced in June 2001, the incidence
rates for serotype 1 invasive infections between the pre-
vaccination (January 1987 to June 2001) and post-vaccination
periods (July 2001 to December 2007) were compared; sig-
niﬁcant increases were observed in the overall population
(v2 Yates = 53.94, p <0.0001) and in the population groups
of 5–14 years (v2 Yates = 5.29, p 0.02), 15–65 years (v2
Yates = 22.19, p >0.0001) and >64 years (v2 Yates = 15.16,
p >0.0001). The increasing incidence in the population aged
<5 years was non-signiﬁcant (v2 Yates = 3.49, p 0.062).
Within the total number of invasive isolates, serotype I
increased through the study period from 2.4% (5/207)
in 1987–1993 and 2.7% (11/405) in 1994–2000, to 12.1%
(72/597) in 2001–2007. Between 1987 and 1995, serotype 1
invasive isolates were isolated only from adults; by the end of
the 1990s, however, serotype 1 was frequent among invasive
isolates from all age groups, at a frequency that markedly
increased in young children compared with adults between
2005 and 2007.
After the introduction of the PCV7, nine children aged
<5 years with serotype 1 invasive disease had pneumonia,
accompanied by pleural effusion in three cases. Seven of
these children had received at least one dose of PCV7.
TABLE 1. Temporal distribution of Streptococcus pneumoniae serotype 1 isolates in Gipuzkoa, northern Spain, from 1987 to
2007 according to sequence types (ST)
Invasive isolates from the population-based area (incidence per million inhabitants) Non-invasive isolates
Overall <5 years 5–14 years 15–64 years >64-years Otic Sputum
1987–1993 5 2 ST228 1 ST304 4 ST304 1
1 ST305 ST3861
1 ST3860
(1.8) (2.0) (2.8)
1994–2000 11 1 ST228 1 ST306 3 ST228 2 ST228 3 ST228 2 ST228
1 ST304 3 ST306 1 ST306 1 ST306
(4.0) (18.6) (4.2) (3.0) (4.6)
2001–2007 72 10 ST306 7 ST306 24 ST306 13 ST306 11 17
5 ST228 6 ST228 ST306 ST306
1 ST228 2 ST227 1 ST227 4 ST227 1 ST228
1 ST304 1 ST305 1 ST228 1 ST227
1 ST217
(25.6)a (78.0) (34.7)a (16.7)a (44.0)a
Total 88 12 9 43 24 24 23
aSigniﬁcant increase in the incidence of each previous period and the 2001–2007 period. No signiﬁcant increase was observed in the incidence between the 1987–1993 and
the 1994–2000 periods.
TABLE 2. Lineages and STs of Streptococcus pneumoniae serotype1 isolates from Gipuzkoa, found between 1987 and 2007
Lineage ST No. of isolates PFGE patterns Years of isolation
Allelic proﬁle
aroE gdh gki recP spi xpt ddl
I 227 8 A5 2002–2006 12 5 13 5 17 4 20
228 24 A1 1993–2007 12 8 1 5 17 4 20
228 1 A6 1994 12 8 1 5 17 4 20
306 81 A2 1998–2007 12 8 13 5 16 4 20
306 7 A3 2004–2006 12 8 13 5 16 4 20
306 1 A4 2006 12 8 13 5 16 4 20
II 304 7 B 1990–2004 13 8 13 5 17 4 8
3861a 1 B 1990 13 10 13 5 17 4 8
305 2 B 1993–2002 13 8 13 5 17 4 28
III 217 1 C 2007 10 18 4 1 7 19 9
Singleton 3860b 1 D 1989 10 5 4 1 6 4 8
PFGE, pulsed-ﬁeld gel electrophoresis; ST, sequence type.
aNew ST.
bNew ST. Typical of serotype 19F.
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Between 1987 and 1998 the distribution of clones showed
wide heterogeneity. ST228 was the predominant clone
among all serotype 1 isolates, representing 61.5% (8/13) of
those causing invasive disease, but its incidence subsequently
decreased to 13.3% (10/75) after 1999 (p <0.001). ST306
appeared for the ﬁrst time in 1998 in the blood culture of a
29-year-old man with pneumonia, and subsequently became
dominant: between 1998 and 2007, ST306 comprised 58/78
(74.4%) of the invasive isolates and 30/39 (76.9%) of non-
invasive isolates.
Some authors have suggested an association between the
increase in the number of invasive pneumococcal disease
cases caused by serotype 1 and the use of the PCV7 [10–
12]. In our study region, a wide circulation of serotype 1 iso-
lates was observed before the introduction of this vaccine,
but a rapid increase in its incidence was observed after the
introduction of the PCV7, with ST306 being the most preva-
lent sequence-type.
This study corroborates ﬁndings in the rest of Europe and
North America that serotype 1 is associated with ST306 and
its related sequence types from the same lineage [1,13–15]
and can therefore be considered to be a clone or group of
clones whose current behaviour is near pandemic.
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